SAN JOSE, Calif.,
April 30,
2024 /PRNewswire/ -- Anixa Biosciences,
Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a
clinical-stage biotechnology company focused on the treatment and
prevention of cancer, today announced its participation in the
Sidoti Micro-Cap Virtual Conference, taking place May 8-9, 2024. Anixa Chairman and CEO Dr.
Amit Kumar will present an overview
of the Company and its clinical programs including vaccines to
prevent cancer and a CAR-T cell therapy to treat cancer.
Conference details:
Presentation:
Thursday, May 9, 2024,
at 11:30 am ET*
Presentation link:
Click here to register; available via Zoom
Conference registration:
Available on the conference website
1x1 meetings:
Open to all investors upon conference
registration
Dr. Kumar will discuss Anixa's preventative breast cancer
vaccine, currently in Phase 1 clinical trials, that is showing
strong positive data. Additional data releases expected in the
coming months, and a Phase 2 trial is expected to commence in early
2025. Anixa's CAR-T cell therapy treatment for ovarian cancer is
also in a Phase 1 trial and showing positive data. Anixa has a
capital efficient business model, with greater than two years cash,
no debt, and a clean cap table.
*The presentation date and time are subject to change.
Participants should refer to the final program agenda for
up-to-date information.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the
treatment and prevention of cancer. Anixa's therapeutic portfolio
consists of an ovarian cancer immunotherapy program being developed
in collaboration with Moffitt Cancer Center, which uses a novel
type of CAR- T, known as chimeric endocrine receptor T-cell (CER-T)
technology. The Company's vaccine portfolio includes a novel
vaccine being developed in collaboration with Cleveland Clinic to
prevent breast cancer – specifically triple
negative breast cancer
(TNBC), the most lethal form of the disease –
as well as a vaccine to prevent ovarian cancer. These vaccine
technologies focus on immunizing against "retired" proteins that
have been found to be expressed in certain forms of cancer. Anixa's
unique business model of partnering with world-renowned research
institutions on clinical development allows the Company to
continually examine emerging technologies in complementary fields
for further development and commercialization. To learn more, visit
www.anixa.com or follow Anixa on Twitter, LinkedIn,
Facebook and YouTube.
Forward-Looking Statements: Statements that are
not historical fact may be considered forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements are not statements of
historical facts, but rather reflect Anixa's current expectations
concerning future events and results. We generally use the words
"believes," "expects," "intends," "plans," "anticipates," "likely,"
"will" and similar expressions to identify forward-looking
statements. Such forward-looking statements, including those
concerning our expectations, involve risks, uncertainties and other
factors, some of which are beyond our control, which may cause our
actual results, performance or achievements, or industry results,
to be materially different from any future results, performance, or
achievements expressed or implied by such forward-looking
statements. These risks, uncertainties and factors include, but are
not limited to, those factors set forth in "Item 1A - Risk Factors"
and other sections of our most recent Annual Report on Form 10-K as
well as in our Quarterly Reports on Form 10- Q and Current Reports
on Form 8-K. We undertake no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law.
You are cautioned not to unduly rely on such forward- looking
statements when evaluating the information presented in this press
release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download
multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-to-participate-in-the-sidoti-micro-cap-virtual-conference-on-may-8--9-2024-302130909.html
SOURCE Anixa Biosciences, Inc.